Our Leadership

Jeff Watson
Jeff Watson

President & Chief Operating Officer

Jeff is President & Chief Operating Officer (COO) of Apotex. Appointed in 2018, Jeff oversees the day-to-day operations of Apotex, including research and development, manufacturing, packaging and distribution of products across three Lines of Business to more than 115 countries around the globe.

Prior to this role, Jeff was President, Global Generics, the largest line of business at Apotex, where he provided leadership for the Commercial and Strategic Operations and was instrumental in delivering significant growth. A 25-year veteran of Apotex, Jeff has held progressively senior positions within Sales and Marketing since 1993 when he joined the company.

Before joining Apotex, Jeff spent time working in the retail pharmacy sector for Shoppers Drug Mart, Canada’s leading pharmacy chain.

Jeff has been a member of the Association for Accessible Medicines (AAM) Board of Directors since 2012 and served as Chair in 2017. He was re-elected as Chair in 2018. In 2008 he became an Executive Member of the Canadian Generic Pharmaceutical Association’s (CGPA) board. From March 2015-February 2017, he served as Chair of CGPA’s board following three years of service as Vice Chair. Jeff is a former Chair of the US Healthcare Distribution Alliance’s (HDA) knowledge partner, the HDA Research Foundation. He is also the Chair of the Board of Directors for TruLeaf Sustainable Agriculture, Nova Scotia, Canada.

Dr Pere Paton
Dr. Pere Paton

President, Global API

Pere joined Apotex Pharmachem in September, 2015 as Vice President and General Manager at the Brantford site. Prior to joining Apotex, Pere spent 18 years in increasing roles of responsibility with Boehringer Ingelheim Pharma in both Europe and the US. While with Boehringer, Pere gained significant experience in API manufacturing as he oversaw operations in Spain, the US and Germany. He has a proven track record driving process improvements to enhance quality, reduce cycle time, increase throughput, and minimize change-over losses to increase network capacity. Pere is a graduate of Universidad de Barcelona where he earned a Ph.D in Chemical Engineering. He also received a Master in Business Adminstration from ESADE Business school.

Dr Klaus Martin
Dr. Klaus Martin

President, Apobiologix

Klaus Martin joined Apotex as President, Apobiologix in January 2018, leading all global development, operational and commercial activities for its biologics business.

Klaus has extensive experience in all stages of biosimilars strategy and development, including the registration and launch strategies of biosimilar products in Europe, North America and Asia.

Klaus joins us from Polpharma Biologics, where he was Chief Scientific Officer overseeing global late stage development and pipeline selection. Klaus simultaneously held the role of Managing Director, Bioceros BV, a division of th​e Polpharma Group that specializes in preclinical development of biosimilars and new biologics.

Before joining Polpharma, Klaus had global development and strategy roles of increasing responsibility in Biopharmaceuticals at Sandoz headquarters where his teams supported biosimilar registrations in the EU, US, CA and JP.

From 2016-2017, Klaus was also Chair of the Market Access Committee of Medicines for Europe's Biosimilars Group, coordinating the industry group's pricing and reimbursement activities in Europe.

Klaus holds an MSc in Biochemistry from Freie Universität Berlin and a PhD in molecular genetics from Cambridge University.

Dr. Michael Spino
Dr. Michael Spino

President, ApoPharma Inc.

Dr. Michael Spino joined Apotex in May 1991 to head up R&D as VP of Scientific Affairs. Prior to that, he was a Professor at the University of Toronto, Faculty of Pharmacy.

Michael obtained his doctorate in Clinical Pharmacy at the University of California, San Francisco Medical Center and then completed a Post-Doctoral Research Fellowship in Toronto. As an academic, in addition to conducting research on drug disposition, he served on several Government advisory committees, most notably the one on Bioequivalence, which founded the clinical criteria for generic drug approvals in Canada.

Within a year of joining Apotex, Michael began his research into the discovery and development of new drugs and set up the Innovative Drug Development Division of Apotex. The success of IDD demanded more of his time and he transitioned out of operating the generic R&D into full-time oversight of IDD, later establishing ApoPharma Inc., a sister company to Apotex, where he became President in 2004. Today, ApoPharma is a profitable company and its R&D pipeline predicts continued growth over the next decade.

Peter Hardwick
Peter Hardwick

Chief Commercial Officer and Executive Vice President of Apotex

Peter is Chief Commercial Officer and EVP of Apotex. Appointed in 2018, Peter has accountability to develop and execute our global commercial strategy for all generic market segments. Peter joined Apotex in 2006 as Director of Marketing Canada and took on expanded roles within the Canadian market where most recently he was the SVP Commercial Operations Canada and Caribbean. Peter has 27 years of Pharma experience in sales and marketing, international management, and held P&L responsibility of core countries within a Global Pharmaceutical company. Peter has both brand and generic experience including five years abroad based in Basel Switzerland working for Mepha Inc. which specialized in branded generics.

In 2016 Peter became a member of the Canadian Generic Pharmaceutical Association's (CGPA) Board and was elected Chair in April 2018. Peter also serves on the board of IMD, a company who specializes in a digital education platform for health care practitioners. He has a BSc in Biology from St. Mary's University, Halifax NS and is a graduate of the Ashridge Executive Management Program, London, UK.

Pradeep Bhadauria
Pradeep Bhadauria

Executive Vice President, Global R&D

As Executive Vice President- Global R&D, Pradeep is responsible for leading the global R&D function focused on delivering high quality, new product submissions for global markets, with particular emphasis on increasing the number of first-to-file submissions in the U.S and strengthening the R&D pipeline of high barrier complex products. In addition, oversight of Global Regulatory Affairs as well as Global API R&D form an integral part of his portfolio today.

Pradeep joined Apotex in June of 2016 as Senior Vice President, Global R&D, bringing with him 20+ years of rich and varied R&D experience in the area of generic product development in many complex dosage forms. Under his leadership. Prior to joining Apotex, he was Vice President, Generic R&D at Actavis Inc. /Allergan Inc. from 2013 to 2016. He also held leadership positions of increasing responsibility with Watson Pharmaceuticals, Sandoz, Catalent, Ranbaxy, Dr. Reddy's and Torrent Pharmaceuticals. Pradeep holds a Master's degree in Pharmaceutics from Birla Institute of Technology, India.

Jordan Berman
​Jordan Berman

VP, Global Corporate Communications

Jordan Berman leads Global Corporate Communications for Apotex. In his role, he is responsible for all communications platforms and channels, reputation management, and for developing and communicating the organization's narrative to a wide variety of stakeholders. Prior to Apotex, Jordan held a Global Communications Leadership role for Johnson & Johnson's medical devices business, a $25 billion organization with 55,000 employees worldwide. For the past 10 years Jordan has held a dual portfolio including both corporate communications and strategic planning, roles he held at AstraZeneca and Johnson & Johnson Medical Companies in Canada. Jordan also spent eight years on the agency side including Vice-President, Health & Pharmaceutical Practice for the Toronto office of Hill & Knowlton, an international communications and public affairs firm. During his consulting tenure, he worked with some of the world's leading health care companies including Pfizer, Medtronic, GlaxoSmithKline and Eli Lilly. Jordan holds a joint Master of Business Administration from the Kellogg School of Management and the Schulich School of Business.

Gordon Fahner
Gordon Fahner

CMA, CPA – SVP, Global Finance

Gordon began his career at Apotex in 1989 and rose to Senior Management in 1993. Throughout 2000-2001, he led our company's SAP implementation. Today, he is responsible for managing the financial risk, planning and reporting for the pharmaceutical operations of the Apotex group. This includes consolidating and analyzing financial data to support executive decision-making. Gordon is also responsible for global financial policies, processes and promoting financial governance across the organization.

Jean-luc Giraud
Jean-Luc Giraud

SVP, Chief Human Resources Officer

Jean-Luc, a French citizen, has brought more than 25 years of diverse experiences in human resources in blue-chip companies such as Mercedes Benz, GE and Sandoz at international levels along with some years as a commercial and marketing leader to his role at Apotex. He is skilled in ensuring talent is well-positioned and recognized, which is critical in delivering leading performance. Since joining Apotex in August 2016, Jean-Luc has led the Human Resources function driving the HR, EHS, and Communication functions while focusing on developing organization, people and talent strategies that aligns with and supports the organization's strategic direction and operational activities. Jean-Luc is an alumni of ESA, ESSEC and Manheim Business schools.

Peter Kalins
Peter Kalins

VP, General Counsel

Peter joined Apotex in 2012, with a mandate to build an in-house legal department. He is responsible for delivering cost-effective legal support on non-IP legal matters for the Apotex group of companies, globally.

Peter is an accomplished General Counsel for both publicly-traded and privately-held global companies, with over 21 years of experience. He started his career as a lawyer in private practice at Torys, a Toronto-based law firm, focusing on corporate and securities law, and then moved to in-house corporate counsel roles, first with Nortel Networks (telecommunications), followed by Magna International (auto parts), and finally with Timminco (metals), before joining Apotex. Peter has builds high performance teams of lawyers and non-legal professionals, and executes projects that enhance the effectiveness, productivity and profile of in-house legal functions. He mitigates legal and reputational risks, and structures and executes complex transactions on a timely and cost-effective basis. Peter has a Bachelor of Commerce and a Bachelor of Laws degrees, both from Queen's University.

Steven Liberty
Steven (Steve) Liberty

EVP, Global Supply and Technical Operations

Steve brings over 30 years' operations leadership experience to Apotex, including 25 years in leading international pharmaceutical manufacturing and supply organizations. In his current role, Steve is responsible for leading Apotex's global finished dosage manufacturing, supply, engineering and technical operations. This includes production and supply sites in Canada, USA, Europe, and India. Prior to joining Apotex in 2013, Steve had a diverse career in the global Pharmaceutical industry with Teva, Patheon, AstraZeneca and Eli Lilly.

Johnny Mikell
Johnny Mikell

SVP, Global Quality Operations

Johnny began his career in pharmaceuticals in 1982 as an Industrial Microbiologist, later growing to head the compliance and quality operations at several major pharmaceutical manufacturers. Johnny holds a BS in Biology and an MS in Microbiology and brings accomplishments from Duke University, London's British Standards Institute, and Harvard University. Johnny joined Apotex in 2015, and is responsible for the global leadership of the Quality and Compliance Group, ensuring compliance with all health authority regulations and sustained product supply while seamlessly developing and executing strategy grounded in our core values.

Ulrich Deutschmann
Ulrich Deutschmann

SVP, Global Business Transformation & Strategic Planning

In June 2017, Ulrich joined Apotex from Sandoz where he served as Head of Strategy. Prior to Sandoz, Ulrich worked with The Boston Consulting Group and A.T. Kearney as a top management consultant. He has extensive global experience with five years working in China and long assignments in Russia, Ukraine, India, South East Asia, Korea and Japan. Trained as an attorney-at-law in Germany, Ulrich started his career with the German specialty chemicals company WACKER Chemie, working in strategic marketing, business development and key account sales. In his capacity, Ulrich has global responsibility for the Apotex Strategy and Strategic Planning processes. He will drive a number of cross-enterprise initiatives around Growth and Cost & Profitability, GBS being one of these.

Kevin Zive
Kevin Zive

VP, Global Intellectual Property

Kevin leads a global team in developing and implementing intellectual property strategies for its generic, biosimilar and branded businesses. As head of intellectual property, Kevin oversees and manages Apotex’s worldwide IP litigation and licensing portfolio, including support of all Hatch-Waxman related activities and proceedings under the PM(NOC) Regulations.

Kevin joined Apotex in December 2010. Prior to joining Apotex, Kevin was a partner at a law firm where he represented multi-national pharmaceutical companies in respect to patent litigation and regulatory matters. Kevin holds a J.D. from Osgoode Hall Law School, a M.Sc. in Neuroscience from McGill University, and bachelor’s degree from the University of Western Ontario. Licensed as both a Canadian and United States attorney, he is a member of the New York State Bar and the Law Society of Upper Canada. Kevin is the Chair of the Intellectual Property Committee for the Canadian Generic Pharmaceutical Association and a member of the Law Committee for the Association of Accessible Medicines.